China repaglinide market report, 2018-2022

Since the 1980s, China's economic development has improved living standards and urbanization level, which significantly increases the incidence of obesity, diabetes and other non-communicable diseases in China.

And population aging and other factors sharply raise the incidence of type 2 diabetes. The number of type 2 diabetic patients in China surpassed 110 million at the end of 2017, and is growing by 1.5 million to 2 million every year, according to a new report offered by ResearchAndMarkets.com.

Insulin secretagogues are mainly used to treat type 2 diabetes. Compared with sulfonylureas, insulin secretagogues have short-lasting effects and cause few hypoglycemia reactions.

Discovered by Germany’s Boehringer Ingelheim, repaglinide is a non-sulfonylurea-based insulin secretagogue used to control postprandial hyperglycemia and was licensed to Danish diabetes care giant Novo Nordisk (NOV: N). The drug, which is marketed by the Danish firm under brand names including GlucoNorm, NovoNorm and Prandin in various countries, was launched in the USA in.1998. Entering China in 2000, Novo Nordisk's NovoNorm has few competitors.